Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.517
-0.030 (-5.47%)
Mar 9, 2026, 1:22 PM EDT - Market open
Ensysce Biosciences Employees
As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$560,997
Profits / Employee
-$1,371,559
Market Cap
1.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | 3 | 100.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 30 |
| Calidi Biotherapeutics | 28 |
| Virax Biolabs Group | 19 |
| Artelo Biosciences | 7 |
| CDT Equity | 6 |
| Adial Pharmaceuticals | 5 |
| CNS Pharmaceuticals | 5 |
| PMGC Holdings | 3 |
ENSC News
- 5 days ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
- 6 days ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
- 10 days ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 12 days ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 14 days ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
- 5 weeks ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 6 weeks ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 2 months ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire